6 completed. 6 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Completed 6 |
Follow Sofosbuvir: new trials by email Literature Review of Sofosbuvir trials Research Report on Sofosbuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of 12 Weeks Versus 24 Weeks Treatment of Directly Acting Antiviral Therapy in Patients With Hepatitis C Related Chronic Liver Disease 12 weeks Sofosbuvir 400 mg once daily, Daclatasvir 60 mg once daily, and Ribavirin 400 mg twice daily - Heptatitis C | Not applicable | Completed | Indus Hospital and Health Network | 192 | 2024-01-10 | 2026-07-14 |
| Twelve Weeks Sofosbuvir/Daclatasvir in HCV Infected Children Aged 6-18 Years Sofosbuvir/Daclatasvir - Hepatitis C,Chronic Children, Only | Not applicable | Completed | National Liver Institute, Egypt | 42 | 2023-12-18 | 2026-10-30 |
| Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure Sofosbuvir, Simeprevir, Daclatasvir - HCV Coinfection | Not applicable | Completed | Assiut University | 40 | 2018-01-01 | 2019-03-19 |
| Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C Sofosbuvir, Ribavirin - Hepatitis C, Chronic, Hepatitis C Virus Infection, Response to Therapy of | Not applicable | Completed | Kawin Technology Share-holding Co., Ltd. | 136 | 2016-08-05 | 2018-03-07 |
| Extrahepatic Insulin Resistance in Chronic Hepatitis C Ledipasvir 90 mg/Sofosbuvir 400 mg, Ribavirin - Insulin Resistance | Not applicable | Completed | University Hospital, Geneva | 17 | 2016-03-01 | 2019-05-01 |
| Management of Decompensated HCV Cirrhotic Patients Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol), vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion - Decompensated Cirrhosis | Not applicable | Completed | Zagazig University | 80 | 2015-06-01 | 2018-12-05 |
Hepatitis C (2) · Hepatitis C, Chronic (1) · Insulin Resistance (1)
Assiut University (1) · Indus Hospital and Health Network (1) · Kawin Technology Share-holding Co., Ltd. (1) · National Liver Institute, Egypt (1) · University Hospital, Geneva (1) · Zagazig University (1)
Egypt (2) · China (1) · Pakistan (1) · Switzerland (1)
Amr S Hanafy, md (1) · Francesco Negro, MD (1) · Hosam M Basiouny, MD (1) · Howyda A El-Bhwashy, MD (1) · Lai Wei, M.D. (1) · Mohamed Mekky, MD (1) · Nermin M Adawy, Prof (1) · Ola A Fouad, MD (1) · Shaimaa G Hegazy, MSC (1)
PMID 10673085, PMID 12407579, PMID 16310281, PMID 26083155, PMID 27482412, PMID 30380158, PMID 30758786, PMID 31531319, PMID 34321444, PMID 36129634